Big Pharma’s 3D Focus
Clive Roberts from the UK's University of Nottingham describes his team's work with big pharma on printing medicines.
Clive Roberts |
My team at the University of Nottingham started work in the area of printing formulations around 2005, based on conversations within our EPSRC (Engineering and Physical Sciences Research Council) Centre for Doctoral Training in Therapeutics. Our discussions with Morgan Alexander, an expert in developing new materials for medical applications, and Paul Gellert, a leading formulation scientist at AstraZeneca, led to a PhD project where we explored the basics of printing formulations and showed the principal of emulating a commercial formulation. Following this successful project, we nevertheless struggled to attract interest in the idea of printing formulations – not so much from sponsors, but from students wanting to take up such a ‘crazy’ project! Eventually, an adventurous student, Shaban Khaled, joined us and took up the challenge. And we got a boost when the EPSRC Centre for Innovative Manufacturing in Additive Manufacturing arrived at the university, along with Ricky Wildman, a professor with expertise in modeling and 3D printing.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine